Rockwell Medical, Inc. to Present at Upcoming September Investor Conferences
September 08 2020 - 8:00AM
Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the
“Company”), a biopharmaceutical company dedicated to transforming
the treatment of iron deficiency and anemia management and
improving outcomes for patients around the world, today announced
the Rockwell Medical executive management team will present at two
upcoming investor conferences in September:
Conference: H.C. Wainwright 22nd Annual Global
Investment Conference Date: September 14, 2020
Time: 4:00 PM EDT Location:
Virtual
Conference: Cantor Fitzgerald Virtual Global
Healthcare Conference Date: September 15, 2020
Time: 10:40 AM EDT Location:
Virtual
The presentations will be webcast live at the
aforementioned time, and archived for 30 days thereafter, via the
Company’s website at www.rockwellmed.com, under the
“Investors” section.
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company
dedicated to transforming anemia management in a wide variety of
therapeutic areas and across the globe, improving the lives of very
sick patients. The Company’s initial focus is the treatment of
anemia in end-stage kidney disease (ESKD). Rockwell
Medical's exclusive renal drug therapies, Triferic (ferric
pyrophosphate citrate) Dialysate and Triferic AVNU, are the only
FDA-approved therapeutics indicated for iron replacement and
maintenance of hemoglobin in hemodialysis patients. Rockwell
Medical is also an established manufacturer, supplier and
leader in delivering high-quality hemodialysis
concentrates/dialysates to dialysis providers and distributors in
the U.S. and abroad.
About Triferic Dialysate and Triferic
AVNU
Triferic Dialysate and Triferic AVNU are the
only FDA-approved therapies in the U.S. indicated to
replace iron and maintain hemoglobin in hemodialysis patients
during each dialysis treatment. Triferic Dialysate and Triferic
AVNU have a unique and differentiated mechanism of action, which
has the potential to benefit patients and health care economics.
Triferic Dialysate and Triferic AVNU represent a potential
innovative medical advancement in hemodialysis patient iron
management – with the potential to become the future standard of
care.
Triferic Dialysate and Triferic AVNU both
deliver approximately 5-7 mg iron with every hemodialysis treatment
to the bone marrow and maintain hemoglobin without increasing iron
stores (ferritin). Both formulations donate iron immediately and
completely to transferrin (carrier of iron in the body) upon entry
into the blood which is then transported directly to the bone
marrow to be incorporated into hemoglobin, with no increase in
ferritin (stored iron and inflammation) and no reports of
anaphylaxis in over 1,000,000 patient administrations, addressing a
significant medical need in overcoming Functional Iron Deficiency
(FID) in ESKD patients.
Important Safety
Information
Serious hypersensitivity reactions, including
anaphylactic-type reactions, some of which have been
life-threatening and fatal, have been reported in patients
receiving parenteral iron products. Patients may present with
shock, clinically significant hypotension, loss of consciousness,
and/or collapse. Monitor patients for signs and symptoms of
hypersensitivity during and after hemodialysis until clinically
stable. Personnel and therapies should be immediately available for
the treatment of serious hypersensitivity reactions.
Hypersensitivity reactions have been reported in 1 (0.3%) of 292
patients receiving Triferic in two randomized clinical trials.
Iron status should be determined on pre-dialysis
blood samples. Post dialysis serum iron parameters may overestimate
serum iron and transferrin saturation.
The most common adverse reactions (≥3% and at
least 1% greater than placebo) in controlled clinical studies
include: procedural hypotension (21.6%), muscle spasms (9.6%),
headache (9.2%), pain in extremity (6.8%), peripheral edema (6.8%),
dyspnea (5.8%), back pain (4.5%), pyrexia (4.5%), urinary tract
infection (4.5%), asthenia (4.1%), fatigue (3.8%), arteriovenous
(AV) fistula thrombosis (3.4%), and AV fistula site hemorrhage
(3.4%).
Triferic® is a registered trademark
of Rockwell Medical, Inc. Triferic AVNU is pending with
the U.S. Patent and Trademark Office.
CONTACTS
Investors: Argot Partners
212.600.1902Rockwell@argotpartners.com
Media: David Rosen Argot Partners
212.600.1902david.rosen@argotpartners.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024